ProMIS Neurosciences Inc.
PMN
Positions held
Your positionsPMN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $82.05M | Enterprise value | $28.59M | Trailing P/E | — | Forward P/E | -2.02 |
| PEG | — | Price / book | 1.66 | Beta | -0.25 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -81.1% | Debt / equity | — |
| Current ratio | 7.86 | Free cash flow | -$26.84M | Analyst recommendation | none | Mean target | $42.57 |
| 52w high | $27.40 | 52w low | $6.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.7M | -$8.2M | -$10.7M | -$11.6M | -$10.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.3M | -$8.6M | -$10.8M | -$11.8M | -$10.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
2026-08-14 · ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
2026-08-14 · Promis Neurosciences Q2 Earnings Call Highlights
2026-08-13 · ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
2026-08-03 · ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
2026-07-28 · Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
2026-07-28 · Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating
2026-07-28 · ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results
2026-07-28 · ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data
Price (daily)
Full chart · RSI · MACD · patterns